<p>.<br /><br />One agreement, with Mylan Inc., lowers the annual price of four antiretroviral drugs that are used as a second line of treatment when patients develop a resistance to the first drugs they are treated with.<br /><br />The other agreement, with Pfizer Inc., reduces the cost of a medication that can be used in conjunction with the drugs in patients who have tuberculosis.<br /><br />The agreements would help drugs "reach hundreds of thousands more people and save hundreds of thousands of more lives. This is a very big deal," Clinton said yesterday in announcing the deal.<br /><br />Clinton said Mylan, through its subsidiary Matrix Laboratories Limited, would bring the annual cost of the antiretroviral drugs atazanavir, ritonavir, tenofovir and lamivudine down to under USD 500.<br /><br />Starting in 2010, the pills will be packaged together and sold as something patients can take once a day, for an annual price of USD 425. The Clinton Foundation said that price is 28 per cent lower than the current lowest-priced alternative.</p>
<p>.<br /><br />One agreement, with Mylan Inc., lowers the annual price of four antiretroviral drugs that are used as a second line of treatment when patients develop a resistance to the first drugs they are treated with.<br /><br />The other agreement, with Pfizer Inc., reduces the cost of a medication that can be used in conjunction with the drugs in patients who have tuberculosis.<br /><br />The agreements would help drugs "reach hundreds of thousands more people and save hundreds of thousands of more lives. This is a very big deal," Clinton said yesterday in announcing the deal.<br /><br />Clinton said Mylan, through its subsidiary Matrix Laboratories Limited, would bring the annual cost of the antiretroviral drugs atazanavir, ritonavir, tenofovir and lamivudine down to under USD 500.<br /><br />Starting in 2010, the pills will be packaged together and sold as something patients can take once a day, for an annual price of USD 425. The Clinton Foundation said that price is 28 per cent lower than the current lowest-priced alternative.</p>